

Manuel Antonio Espinoza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2186286/publications.pdf>

Version: 2024-02-01

28
papers

630
citations

759233

12
h-index

610901

24
g-index

37
all docs

37
docs citations

37
times ranked

1271
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a high-risk multimorbidity integrated care implemented at the public health system in Chile. PLoS ONE, 2022, 17, e0261953.	2.5	6
2	Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-9.	1.4	0
3	Development of a checklist to guide equity considerations in health technology assessment. International Journal of Technology Assessment in Health Care, 2021, 37, e17.	0.5	16
4	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. PLoS Medicine, 2021, 18, e1003415.	8.4	72
5	Prevalence, burden of disease, and lost in health state utilities attributable to chronic musculoskeletal disorders and pain in Chile. BMC Public Health, 2021, 21, 937.	2.9	10
6	A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile. Pharmacoeconomics - Open, 2021, 5, 635-647.	1.8	3
7	Value in Health Regional Issues: Reflections and Challenges After a Decade. Value in Health Regional Issues, 2021, 25, 180-181.	1.2	0
8	Different Alternatives to Assess the Burden of Disease Using Attributable Fraction on a Disability Variable: The Case of Pain and Chronic Musculoskeletal Disorders in Chile. Value in Health Regional Issues, 2021, 26, 15-23.	1.2	2
9	Using Telenephrology to Improve Access to Nephrologist and Global Kidney Management of CKD Primary Care Patients. Kidney International Reports, 2020, 5, 920-923.	0.8	10
10	The impact of hypoglycemia on healthcare costs: a modeling study from Chile. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, , 1-6.	1.4	1
11	The Value of Further Research: The Added Value of Individual-Participant Level Data. Applied Health Economics and Health Policy, 2019, 17, 273-284.	2.1	3
12	Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. Value in Health, 2019, 22, 739-749.	0.3	47
13	Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 609-617.	1.4	1
14	Evaluation of the Health Assessment Questionnaire Disability Index in Chilean patients with rheumatoid arthritis. Revista Medica De Chile, 2019, 147, 612-617.	0.2	6
15	Critical Analysis of Markov Models Used for the Economic Evaluation of Colorectal Cancer Screening: A Systematic Review. Value in Health, 2018, 21, 858-873.	0.3	28
16	Social value and individual choice: The value of a choice-based decision-making process in a collectively funded health system. Health Economics (United Kingdom), 2018, 27, e28-e40.	1.7	2
17	Costs and consequences of chronic pain due to musculoskeletal disorders from a health system perspective in Chile. Pain Reports, 2018, 3, e656.	2.7	30
18	Out-of-Pocket Expenditures in Health and Medications in Chile: Comparative Analysis Between 1997, 2007, and 2012. Value in Health Regional Issues, 2018, 17, 202-209.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Knowledge Translation in Practice: Exploring the Potential Use of MCDA in Central America and the Caribbean. Value in Health Regional Issues, 2018, 17, 148-149.	1.2	1
20	Evaluaci3n de tecnolog3as sanitarias para la toma de decisiones y la rendici3n de cuentas: una urgente reflexi3n para el sistema de salud chileno. Value in Health Regional Issues, 2017, 14, 33-34.	1.2	1
21	VISIONS OF STAKEHOLDERS ABOUT INSTUTIONALIZATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHILE: A QUALITATIVE STUDY. International Journal of Technology Assessment in Health Care, 2017, 33, 303-306.	0.5	4
22	Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud p3blico chileno. Value in Health Regional Issues, 2017, 14, 28-32.	1.2	1
23	Did Socioeconomic Inequality in Self-Reported Health in Chile Fall after the Equity-Based Healthcare Reform of 2005? A Concentration Index Decomposition Analysis. PLoS ONE, 2015, 10, e0138227.	2.5	24
24	Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Na~ve Patients in Chile. PLoS ONE, 2015, 10, e0141660.	2.5	13
25	The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis. Medical Decision Making, 2014, 34, 951-964.	2.4	67
26	The power of chameleonic ideas in the policy decision-making process: the case of the 'students' revolution' in Chile. Journal of Education for Teaching, 2012, 38, 509-511.	2.0	1
27	Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients. Obesity Surgery, 2010, 20, 1400-1407.	2.1	24
28	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Journal of Hepatology, 2007, 47, 412-417.	3.7	180